Total trials
75
Active
14
Phase 3
12
Total enrollment
10,438
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Toludesvenlafaxine Hydrochloride Sustained-release | — | — | — | — | — | 1 | |
| Topotecan | — | — | — | — | — | 2 | |
| Lurbinectedin | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Irinotecan hydrochloride liposome | — | — | — | — | — | 1 | |
| LY03020 | — | — | — | — | 4 | ||
| LPM6690176 | — | — | — | — | 2 | ||
| Bevacizumab | — | — | — | — | 2 | ||
| LPM3770164 sustained release tablet simulant | — | — | — | — | 3 | ||
| LY01021 | — | — | — | — | — | 1 | |
| FOLFIRI | — | — | — | — | — | 1 | |
| LPM3770164 sustained release tablet 5 mg | — | — | — | — | — | 1 | |
| LPM3770164 sustained release tablet 10 mg | — | — | — | — | — | 1 | |
| LPM3770164 sustained release tablet 20 mg | — | — | — | — | — | 1 | |
| LY03017 | — | — | — | — | — | 3 | |
| LY03017-Placebo | — | — | — | — | — | 2 | |
| [14C] LPM3770164 | — | — | — | — | — | 1 | |
| LY03021 | — | — | — | — | — | 1 |
Next readouts
- 2025-08-27
- 2025-10
- 2025-10-31
- 2025-10-31
- 2025-12-31
- 2025-12-31
- 2026-02
- 2026-04-30
- 2026-06-30
- 2027-02-28
Top conditions
- Schizophrenia10
- Parkinson Disease9
- Major Depressive Disorder7
- Huntington Disease4
- Schizoaffective Disorder4
- Alzheimer's Disease Psychosis4
- Healthy4
- Healthy Adults3
Frequently asked questions about Luye Pharma Group Ltd.
- How many clinical trials does Luye Pharma Group Ltd. have on ClinicalTrials.gov?
- Luye Pharma Group Ltd. is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Luye Pharma Group Ltd.'s trials are in Phase 3?
- 12 of Luye Pharma Group Ltd.'s trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does Luye Pharma Group Ltd. focus on?
- Luye Pharma Group Ltd.'s most-studied conditions on ClinicalTrials.gov are Schizophrenia, Parkinson Disease, Major Depressive Disorder, Huntington Disease, Schizoaffective Disorder.
- When are Luye Pharma Group Ltd.'s next clinical trial readouts?
- Luye Pharma Group Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Food Effect Study of LY03020 in Healthy Subjects”, expected around 2025-08-27.